- Relationship between clinicopathological features and platelet count levels in patients with advanced gastric cancer following chemotherapy.
| Clinical characteristics | Total (n=259) | Pre-treatment PLT | Post-treatment PLT | Dynamic change | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| >300×109/L | ≤300×109/L | P-values | >300×109/L | ≤300×109/L | P-values | Increase | Decrease | P-values | ||
| Age (years) | ||||||||||
| >60 | 130 (50.2) | 101 (77.7) | 29 (22.3) | 1.000 | 111 (85.4) | 19 (14.6) | 0.598 | 92 (70.8) | 38 (29.2) | 0.270 |
| ≤60 | 129 (49.8) | 100 (77.5) | 29 (22.5) | 114 (88.4) | 15 (11.6) | 82 (63.6) | 47 (36.4) | |||
| Gender | ||||||||||
| Male | 196 (75.2) | 151 (77.0) | 45 (23.0) | 0.542 | 168 (85.7) | 28 (14.3) | 0.123 | 130 (66.3) | 66 (33.7) | 1.000 |
| Female | 63 (24.8) | 50 (79.4) | 13 (20.6) | 57 (90.5) | 6 (9.5) | 44 (69.8) | 19 (30.2) | |||
| Regimen | ||||||||||
| Paclitaxel-based | 166 (64.1) | 126 (75.9) | 40 (24.1) | 0.193 | 146 (88.0) | 20 (12.0) | 0.529 | 120 (72.3) | 46 (27.7) | 0.109 |
| Fluorouracil-based | 46 (17.8) | 41 (89.1) | 5 (10.9) | 40 (87.0) | 6 (13.0) | 25 (54.3) | 21 (45.7) | |||
| Fluorouracil and paclitaxel | 42 (16.2) | 30 (71.4) | 12 (28.6) | 34 (81.0) | 8 (19.0) | 26 (61.9) | 16 (38.1) | |||
| Other | 5 (1.9) | 4 (80.0) | 1 (20.0) | 5 (100.0) | 0 (0.0) | 3 (60.0) | 2 (40.0) | |||
| Tumor site | ||||||||||
| Gastric antrum | 35 (13.5) | 25 (71.4) | 10 (28.6) | 0.808 | 28 (80.0) | 7 (20.0) | 0.455 | 25 (71.4) | 10 (28.6) | 0.751 |
| Stomach cardia | 100 (38.6) | 78 (78.0) | 22 (22.0) | 87 (87.0) | 13 (13.0) | 65 (65.0) | 35 (35.0) | |||
| Crossing | 50 (19.3) | 39 (78.0) | 11 (22.0) | 46 (92.0) | 4 (8.0) | 36 (72.0) | 14 (28.0) | |||
| Gastric body | 74 (28.6) | 59 (79.7) | 15 (20.3) | 64 (86.5) | 10 (13.5) | 48 (64.9) | 26 (35.1) | |||
| Pathological type | ||||||||||
| Tubular adenocarcinoma | 101 (39.0) | 75 (74.3) | 26 (25.7) | 0.661 | 87 (86.1) | 14 (13.9) | 0.339 | 68 (67.3) | 33 (32.7) | 0.713 |
| Signet ring cell carcinoma | 55 (21.2) | 41 (74.5) | 14 (25.5) | 44 (80.0) | 11 (20.0) | 35 (63.6) | 20 (36.4) | |||
| Mucinous adenocarcinoma | 27 (10.4) | 22 (81.5) | 5 (18.5) | 24 (88.9) | 3 (11.1) | 18 (66.7) | 9 (33.3) | |||
| Papillary carcinoma | 59 (22.8) | 49 (83.1) | 10 (16.9) | 55 (93.2) | 4 (6.8) | 39 (66.1) | 20 (33.9) | |||
| Other | 17 (6.6) | 14 (82.4) | 3 (17.6) | 15 (88.2) | 2 (11.8) | 14 (82.4) | 3 (17.6) | |||
| Metastasis | ||||||||||
| Organ* | 112 (43.2) | 88 (78.6) | 24 (21.4) | 0.809 | 97 (86.6) | 15 (13.4) | 0.622 | 77 (68.8) | 35 (31.3) | 0.183 |
| Distant lymph node† | 32 (12.4) | 23 (71.9) | 9 (28.1) | 30 (93.8) | 2 (6.2) | 24 (75.0) | 8 (25.0) | |||
| Peritoneal | 59 (22.8) | 45 (76.3) | 14 (23.7) | 51 (86.4) | 8 (13.6) | 33 (55.9) | 26 (44.1) | |||
| Multi-site‡ | 56 (21.6) | 45 (80.4) | 11 (19.6) | 47 (83.9) | 9 (16.1) | 40 (71.4) | 16 (28.6) | |||
| Borrmann type | ||||||||||
| I | 43 (16.6) | 27 (62.8) | 16 (37.2) | 0.035** | 41 (95.3) | 2 (4.7) | 0.065 | 30 (69.8) | 13 (30.2) | 0.164 |
| II | 76 (29.3) | 57 (75.0) | 19 (25.0) | 67 (88.2) | 9 (11.8) | 56 (73.7) | 20 (26.3) | |||
| III | 103 (39.8) | 86 (83.5) | 17 (16.5) | 83 (80.6) | 20 (19.4) | 61 (59.2) | 42 (40.8) | |||
| IV | 37 (14.3) | 31 (83.8) | 6 (16.2) | 34 (91.9) | 3 (8.1) | 27 (73.0) | 10 (27.0) | |||
Values are presented as numbers and precentages (%).
PLT: platelet count
↵* Include liver, lung, ovary, pancreas, colon, and bone.
↵† Next to the aorta, superior mesenteric, retroperitoneal and supraclavicular lymph nodes.
↵‡ Include distant organ and lymph node metastasis simultaneously; distant organ and peritoneal metastasis simultaneously; distant lymph node and peritoneal metastasis simultaneously; distant organ, distant lymph node and peritoneal metastasis simultaneous.
↵** A p-value of <0.05 is statistically significant using Chi-square test.